{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Avalon GloboCare Corp. overvalued or undervalued?
Avalon GloboCare Corp. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of -1.66, an EV to EBITDA ratio of -2.64, and a troubling ROCE of -180.71%, which positions it unfavorably compared to peers like CohBar, Inc. and Atreca, Inc.
Is Avalon GloboCare Corp. technically bullish or bearish?
As of June 10, 2025, the technical trend has shifted to a bearish stance, supported by bearish weekly MACD, daily moving averages, and weekly KST, despite some mildly bullish monthly indicators.
Who are in the management team of Avalon GloboCare Corp.?
As of March 2022, Avalon GloboCare Corp.'s management team includes Mr. Lu Wenzhao (Chairman), Dr. David Jin (CEO), and Ms. Li Meng (COO). The Board of Directors also features independent directors such as Mr. Wilbert Tauzin and Mr. Steven Sanders.
What does Avalon GloboCare Corp. do?
Avalon GloboCare Corp. is a biotech developer and healthcare service provider in the Pharmaceuticals & Biotechnology industry, currently reporting net sales of $0 million and a net loss of $2 million as of March 2025, with a market cap of $6.47 million.
How big is Avalon GloboCare Corp.?
As of Jun 18, Avalon GloboCare Corp. has a market capitalization of 6.47 million, with net sales of 1.38 million and a net profit of -9.01 million over the latest four quarters. Shareholder's funds are reported at 7.10 million, and total assets amount to 20.99 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
